Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this recruitment plan (ADAPT-SCR) is to collect image and other data on both digital breast tomosynthesis (DBT) and full-field digital mammography (FFDM) from asymptomatic women undergoing screening mammography.
ADAPT program consists of 2 recruitment plans (ADAPT-SCR and ADAPT-BX) followed by an off-line read of the images and data collected (ADAPT-BIE). This study involves the comparison of two devices that can identify abnormalities in routine breast screening and diagnostic mammography. Mammography is usually done with full-field digital mammography (FFDM), which takes flat, two-dimensional X-ray images of the breast. Doctors use the two-dimensional images to look for cancers and other abnormal tissue. The purpose of this study is to learn more about the accuracy of full-field digital mammography devices and a new mammography device called digital breast tomosynthesis (DBT). DBT is similar to full-field digital mammography, but can also move around the breast to get X-ray images from different angles, which provides a three-dimensional view that doctors can use to look for cancers and abnormal tissue. Subjects will undergo routine imaging with FFDM and will also have a DBT performed. They will continue with their standard of care treatment as would occur outside of the study. Based on the results of the FFDM and DBT, the subject's status will be followed-up with routing imaging at approximately 1 year (10-16 months). If the doctor recommends biopsy based on the FFDM or DBT, information about the biopsy and cancer determination results will be collected. Being in this study does not require subjects to have a biopsy that was not recommended by the doctor for normal medical care.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| DBT and FFDM | Other | Subjects will undergo 2D breast imaging with full-field digital mammography (FFDM) device (active comparator) and 3D breast imaging with digital breast tomosynthesis (DBT) device (experimental). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| FFDM | Device | 2D imaging of the breast using Full-Field Digital Mammography (FFDM) device |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Imaging Data Collected | Collect breast image data using two (2) methods: Digital Breast Tomosynthesis (DBT) and Full Field Digital Mammography (FFDM) from asymptomatic women undergoing screening mammography. | within 30 days of enrollment |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Device Malfunctions by Modality (DBT or FFDM). | Number of device malfunctions by modality (DBT or FFDM) | Duration of study -approximately 26 months |
| Cancer-positive Participants | Participants confirmed to be positive for cancer on histology review. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Murray Rebner, MD | Beaumont Health | Principal Investigator |
| William Poller, MD | West Penn Allegheny Health System | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Beaumont Health System | Royal Oak | Michigan | 48073 | United States | ||
| Allegheny General Hospital |
Individual participant data (IPD) will not be shared with other researchers
Not provided
Not provided
Not provided
Not provided
Not provided
The subject population consisted of asymptomatic adult women (30 years of age or greater) scheduled for routine screening mammography.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Mammography FFDM and DBT | All subjects were expected to undergo 2D breast imaging with full-field digital mammography (FFDM) and 3D breast imaging with digital breast tomosynthesis (DBT). The order in which these scans took place was not assigned. Digital Breast Tomosynthesis: 3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device Full-Field Digital Mammogram: 2D imaging of the breast using Full-Field Digital Mammography (FFDM) device |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
The analysis population consisted of asymptomatic adult women (>30 years of age) scheduled for routine screening mammography. All women followed the same participant flow plan, and were all considered to be in the same single arm of the study.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Mammography FFDM and DBT | All subjects underwent 2D breast imaging with full-field digital mammography (FFDM) followed by 3D breast imaging with digital breast tomosynthesis (DBT). Order for scan method was not assigned. Digital Breast Tomosynthesis: 3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device Full-Field Digital Mammogram: 2D imaging of the breast using Full-Field Digital Mammography (FFDM) device |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With Imaging Data Collected | Collect breast image data using two (2) methods: Digital Breast Tomosynthesis (DBT) and Full Field Digital Mammography (FFDM) from asymptomatic women undergoing screening mammography. | The efficacy population for primary outcome were subjects meeting study inclusion/exclusion criteria with no protocol violations judged to affect the ability to evaluate the subject, whose DBT/FFDM images were diagnostically evaluable and whose mammography images were available for independent blinded evaluation, regardless of image quality. | Posted | Count of Participants | Participants | within 30 days of enrollment |
|
Time frame in which subjects were to complete the two scan types (up to 30 days).
Adverse Event (AE): As defined by European Norms International Standard Organization (EN ISO) ISO 14155-2011: any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related to the investigational medical device.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Mammography FFDM and DBT | Subjects underwent 2D breast imaging with full-field digital mammography (FFDM) followed by 3D breast imaging with digital breast tomosynthesis (DBT). Digital Breast Tomosynthesis: 3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device Full-Field Digital Mammogram: 2D imaging of the breast using Full-Field Digital Mammography (FFDM) device |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Rash | Skin and subcutaneous tissue disorders | EN ISO 14155-2011 | Non-systematic Assessment |
The aim of this study (ADAPT-SCR) was to collect image data using two methods from asymptomatic women undergoing screening mammography. No statistical hypothesis was tested in this image collection study.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Sara Lam | GE Healthcare | 1-262-548-2369 | Sara.J.Lam@ge.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jun 15, 2016 | Nov 13, 2018 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D008327 | Mammography |
| ID | Term |
|---|---|
| D011859 | Radiography |
| D003952 | Diagnostic Imaging |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| DBT | Device | 3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device |
|
|
| Duration of study - approximately 26 months |
| Pittsburgh |
| Pennsylvania |
| 15212 |
| United States |
| years |
|
| Sex: Female, Male | Per Inclusion/Exclusion criteria, all study participants were female | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
| Successfully completed FFDM and DBT scans | This baseline measure includes enrolled participants who successfully completed both DBT and FFDM scans. | Count of Participants | Participants |
|
|
|
| Other Pre-specified | Device Malfunctions by Modality (DBT or FFDM). | Number of device malfunctions by modality (DBT or FFDM) | One device malfunction reported for FFDM; Zero device malfunctions reported for DBT. | Posted | Number | Malfunctions | Duration of study -approximately 26 months |
|
|
|
| Other Pre-specified | Cancer-positive Participants | Participants confirmed to be positive for cancer on histology review. | Participants who completed the study, including conclusive histology review, and cancer status was positive. | Posted | Count of Participants | Participants | Duration of study - approximately 26 months |
|
|
|
| 0 |
| 250 |
| 0 |
| 250 |
| 2 |
| 250 |
Not provided
Not provided
| D017437 |
| Skin and Connective Tissue Diseases |